Background
Meta-analyses have shown that progesterone (P) elevation is associated with a decreased probability of pregnancy achievement in fresh in vitro fertilization (IVF) cycles. The objective of this study is to evaluate the P level, the P to oocyte ratio (P/O) and the P to follicle (> 14 mm) ratio (P/F) in prediction of successful pregnancy in different age groups.
Methods
This was a retrospective, single-centre cohort study with 1517 cycles performed in 1305 patients undergoing controlled ovarian stimulation and fresh embryo transfer cycles between 2015 and 2021. We investigated the association of serum progesterone level on the day of ovulation trigger with live birth among patients age ≤ 35 (group 1), 36–39 (group 2) and ≥ 40 (group 3).
Results
The progesterone level was significantly associated with the live birth rate in group 1 (aOR 0.422, 95% CI 0.231–0.770, p = 0.005), but not in group 2 (aOR 0.626, 95% CI 0.362–1.084, p = 0.095) and group 3 (aOR 0.311, 95% CI 0.042–2.284, p = 0.251). The live birth rate was significantly reduced in group 1 with P > 1.00 ng/mL (36.8% vs. 23.6%, p = 0.002). No significant difference in the live birth rate was found with P > 1.00 ng/mL in both groups 2 and 3. Both the P/O and P/F ratios, though were more predictive than P alone in live birth rate among all age groups, the values increased substantially with age.
Conclusions
Our results suggest that progesterone elevation is less predictive to live birth rate among patients age above 35. While the P/O or P/F ratio are significantly higher among women without live birth in all 3 age groups, their age-dependent values suggest the definition of a universal threshold should be warranted.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.